The science — two problems in one tablet

A tablet must solve two entirely separate physical problems at once, and they pull in opposite directions. Almost everything about how these products are designed, priced and defended competitively flows from this single split. Master this section and the rest of the report is just application.

Figure 2.1 — The two problems. The tablet must be strong enough to survive manufacture and shipping, and weak enough to fall apart on schedule inside a patient. They are tuned by different levers, and they fail in completely different ways.

Problem one — the tablet has to survive being made

A tablet press fills a steel die with loose powder, hits it with ten to thirty kilonewtons, and ejects a solid object — up to several hundred thousand times an hour. Two things have to work. First, the powder must flow: it has to fall into the die reproducibly, or tablet weights vary and the batch fails uniformity. Second, the powder must compact: the particles have to bond into a solid that resists breaking.

Materials bond under pressure in one of two ways. Brittle materials — lactose, dicalcium phosphate — fracture into fresh fragments that lock together. Plastic materials deform permanently and create large areas of intimate contact. Microcrystalline cellulose is the outstanding plastic filler: it deforms rather than shatters, producing exceptionally hard tablets at modest compression force. That single mechanical property, discovered in the 1950s, is why MCC became and remains the most widely used tablet filler on earth.

This problem is forgiving. It shows up immediately, on the press, in numbers an operator can read: tablet hardness, friability, weight variation, capping. If it goes wrong you know within an hour and you fix it by changing the blend or the force. It is engineering by adjustment.

Problem two — the tablet has to give the dose back, for years

Having built something deliberately hard, the formulator now needs it to fall apart in minutes in the gut, release the API into solution, and keep doing exactly that for a shelf life of two to three years across every climate the product is sold into. Disintegration is handled by a disintegrant — croscarmellose sodium, sodium starch glycolate, crospovidone — a polymer that absorbs water and swells several times its volume, blowing the compact apart from within.

This is where the industry's real difficulty lives, for three reasons.

• The failure is invisible at release. A tablet that passes every test today can fail dissolution at the twelve-month stability pull — eighteen months after the batch was made, and long after the same material went into a dozen other products.
• The causes are present in parts per million. Residual peroxides in a binder can oxidise a sensitive API. Aldehydes in a cellulose ether can react with an amine drug to contribute to nitrosamine formation — the impurity class that has driven repeated global product recalls and is now the subject of a standardised industry risk-assessment questionnaire, updated by the IPEC Federation in 2025.
• Moisture moves. MCC typically carries a few percent water. That water is harmless in most formulations and quietly destroys a moisture-sensitive API in others — which is why low-moisture grades exist and sell at a premium.

So the excipient maker is defending against an invisible, time-delayed enemy using process control and analytical rigour, on a material the customer will not re-test from scratch. It is engineering by prevention, and it is the opposite of forgiving.

Why this makes a commodity look like a specialty

Here is the fact that surprises every newcomer. Microcrystalline cellulose is not a protected molecule. Its chemistry is public, unpatented and roughly seventy years old: take purified wood pulp, hydrolyse away the amorphous regions with dilute acid, wash, neutralise, dry, mill. A competent chemical engineer can make cellulose powder in a week.

And yet the pharmaceutical grades of that same material sustain durable pricing, long customer relationships and mid-to-high-teens margins, while the technical grades sell as a low-margin commodity. The difference is not in the molecule. It is in the particle, the consistency and the dossier — the three things Section 3 is about.